724MO Balstilimab (anti-PD-1) in combination with zalifrelimab (anti-CTLA-4): Final results from a phase II study in patients (pts) with recurrent/metastatic (R/M) cervical cancer (CC)
| Autor: | O'Malley, D., Neffa, M., Monk, B.J., Melkadze, T., Kryzhanivska, A., Bulat, I.V., Meniawy, T., Bondarenko, I., Ortuzar Feliu, W.I., Ancukiewicz, M., Lugowska, I. |
|---|---|
| Zdroj: | In Annals of Oncology September 2021 32 Supplement 5:S727-S727 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|